Invest in PhorMed

The company anticipates a clear path toward an open and ever-growing marketplace. Our planned GO-PUBLIC translation offers our investors an exit strategy

We save lives by treating life-threatening diseases, repairing damaged cells, killing cancer cells to destroy cancer at its core

Our *platform drug reverses disease utilizing cell repair therapy to target damaged and mutated cells, having the ability to fix various cell types and kill cancer cells. Additionally, our drug boosts the immune system’s ability to fight cancer, an activity called immunotherapy. The drug is administered through intravenous infusions (I.V. drip).

*Platform is defined as one drug applied across many applications.

Many common life-threatening diseases have few to no treatment options or require dangerous treatments with long-lasting side effects

Many patients are often faced with the harsh reality of either no viable treatment options or, in cases like cancer, having to endure harmful and painful treatments with severe, long-lasting, and possible organ-damaging side effects. These harsh treatments can increase the already high chance of relapse.  In some cases, severe side effects show up years after treatment.

Our platform drug shows unparalleled promise in curing  cancer and various other deadly diseases, giving patients the opportunity to reclaim their health and live fuller lives

We are currently in clinical trials, advancing the development of our platform drug, RP-323. This treatment targets life-threatening diseases like Acute Myeloid Leukemia (AML/cancer), Hodgkin’s Lymphoma (cancer), Parkinson’s disease (brain disorder), and Acute Respiratory Distress Syndrome (ARDS/lung disorder).

Our technology is a targeted therapy that can repair a variety of damaged and mutated cells while killing cancer cells to directly attack cancer at its root. 

(Watch the Video Below!)

While we actively work on our go-public transaction, we continue to evaluate partnership opportunities for ongoing R&D and future distribution, allocating funds in the most efficient manner to achieve our primary goal: clinical success and saving lives.

Our cell repair therapy:

•      Helped 83% of our AML patients beat cancer

•      Delivers significant tumor reduction in Hodgkin's Lymphoma

•      Reduces lung inflammation, a key driver of ARDS, helping patients breathe again.

•      Reduces brain inflammation, addressing a major factor in Parkinson’s disease progression

•      Earned FDA has Fast-Tracked Phase 1 and Phase 2 for both our cancer studies

•      Increases White Blood Cells (WBC) & Neutrophils (NEUT)

*(WBC & NEUT are part of the cancer-fighting immune system - see image below)

Our treatments set a new standard by prioritizing safety and effectiveness, tackling diseases at their root cause rather than merely alleviating symptoms

While current treatment options for some diseases can cause devastating side effects and possibly damage internal organs and healthy cells, particularly with cancer drugs, other disease states like Parkinson's and ARDS are limited to treatments only relieving symptoms. 

Our drug changes that. It targets the underlying cause of these diseases, protecting organs and healthy cells from being damaged. We aim to offer safe and targeted treatments in places where they are not currently available.

Our drug has been proven to be safe in early studies

The Phase I Study has been completed, establishing the safety validity of our drug. We are now in Phase II in 3 of our clinical studies.

These deadly diseases are widespread, with many untapped markets clear of competition

Currently, the only medicines available for indications (medical conditions) like ARDS and Parkinson’s are symptom-treating drugs. We would control large sectors of the market void of completion with our targeted disease-focused treatments.

Qualifications:

• Phase 3: 0 clinical trials (all companies have zero trials in Phase 3).
• Phase 2: 2 or 3 clinical trials (PhorMed has the advantage with 3 clinical trials at this stage compared to others with only 2).
• Phase 1 & Pre-Clinical: All have additional clinical trials and studies in development.

With projected market values ranging between $290M-$1.2B, PhorMed has remarkable growth potential at just $53 million. Invest now and grow with the company.